

**PHARMACOLOGY**

**SEMESTER I**

## Programme Outcomes

Postgraduates students will be able to:

**PO1: Fundamentals on advanced analytical instrumental techniques:** UV-Visible, IR, Spectrofluorimetry, Flame emission and Atomic absorption spectroscopy, NMR spectroscopy, Mass Spectroscopy, Chromatography, Electrophoresis and Immunological assays methods.

**PO2: Advanced knowledge in field of pharmacology:** Pharmacokinetics, Pharmacodynamics, Neurotransmission, Systemic Pharmacology, pathophysiology of diseases, Parasympathomimetics and lytics, sympathomimetics and lytics, Central nervous system, cardiovascular and autonomic Pharmacology.

**PO3: knowledge on preclinical evaluation of drugs and recent experimental techniques in the drug discovery:** Common laboratory animals, Anaesthesia and euthanasia of experimental animals, Bioassay, Preclinical screening of new substances for the pharmacological activity, Preclinical screening of new substances, immunoassay.

**PO4: Fundamental knowledge on the structure and functions of cellular components:** Cell biology, cell cycle and its regulation, Cell death, Cell signaling, genomic and proteomic tools, intracellular signaling pathways, Recombinant DNA technology and gene therapy, Pharmacogenomics.

**PO5: Knowledge of recent advances in the drugs used for the treatment of various diseases:** Endocrine Pharmacology, Chemotherapy, Immunopharmacology, GIT Pharmacology, Chronopharmacology, Free radicals Pharmacology.

**PO6: Imparts knowledge on the preclinical safety and toxicological evaluation of drug:** OECD, ICH, EPA and Schedule Y, Reproductive toxicology studies, Genotoxicity studies, In vivo carcinogenicity studies, Toxicokinetics.

**PO7: Knowledge of drug discovery, clinical research and pharmacovigilance:** lead identification and lead Optimization, Economics of drug discovery, Rational Drug Design, Molecular docking, 3D-QSAR approaches like COMFA and COMSIA, Good Clinical Practice (ICH-GCP) guidelines, Pharmacoepidemiology, pharmacoeconomics.

**PO8: Knowledge about Research Methodology & Biostatistics:** review of literature, strategies to eliminate errors/bias, values in medical ethics, CPCSEA guidelines for laboratory animal facility, Declaration of Helsinki.

## MODERN PHARMACEUTICAL ANALYTICAL TECHNIQUES (MPC 101T)

### Scope

This subject deals with various advanced analytical instrumental techniques for identification, characterization and quantification of drugs. Instruments dealt are NMR, Mass spectrometer, IR, HPLC, GC etc.

### Objectives

After completion of course student is able to know,

- Chemicals and Excipients
- The analysis of various drugs in single and combination dosage forms
- Theoretical and practical skills of the instruments

### THEORY

60

### HOURS

1. a. UV-Visible spectroscopy: Introduction, Theory, Laws, Instrumentation associated with UV-Visible spectroscopy. Choice of solvents and solvent effect and Applications of UV-Visible spectroscopy. 10 Hrs
- b. IR spectroscopy: Theory, Modes of Molecular vibrations, Sample handling, Instrumentation of Dispersive and Fourier – Transform IR Spectrometer, Factors affecting vibrational frequencies and Applications of IR spectroscopy.
- c. Spectrofluorimetry: Theory of Fluorescence, Factors affecting fluorescence, Quenchers, Instrumentation and Applications of fluorescence spectrophotometer.
- d. Flame emission spectroscopy and Atomic absorption spectroscopy: Principle, Instrumentation Interference and Applications.
- e.
2. NMR spectroscopy: Quantum numbers and their role in NMR, Principle, Instrumentation, Solvent requirement in NMR, Relaxation process, NMR signals in various compounds, Chemical shift, Factors influencing chemical shift, Spin-Spin coupling, Coupling constant, Nuclear magnetic double resonance, 10 Hrs

Brief outline of principles of FT-NMR and  $^{13}\text{C}$  NMR. Applications of NMR spectroscopy.

Mass Spectroscopy: Principle, Theory, Instrumentation of Mass Spectroscopy, Different types of ionization like electron impact, chemical, field, FAB and MALDI, APCI, ESI, APPI Analyzers of Quadrupole and Time of Flight, Mass fragmentation and its rules, Meta stable ions, Isotopic peaks and Applications of Mass spectroscopy

Chromatography: Principle, apparatus, instrumentation, chromatographic parameters, factors affecting resolution, isolation of drug from excipients, data interpretation and applications of the

following:

- j) Thin Layer chromatography
- k) High Performance Thin Layer Chromatography
- l) Ion exchange chromatography
- m) Column chromatography
- n) Gas chromatography
- o) High Performance Liquid chromatography
- p) Ultra High Performance Liquid chromatography
- q) Affinity chromatography
- r) Gel Chromatography

Electrophoresis: Principle, Instrumentation, Working conditions, factors affecting separation and applications of the following:

- a) Paper electrophoresis
- b) Gel electrophoresis
- c) Capillary electrophoresis
- d) Zone electrophoresis
- e) Moving boundary electrophoresis
- f) Iso electric focusing

X ray Crystallography: Production of X rays, Different X ray diffraction methods, Bragg's law, Rotating crystal technique, X ray powder technique, Types of crystals and applications of X-ray diffraction.

Potentiometry: Principle, working, Ion selective Electrodes and Application of potentiometry.

Thermal Techniques: Principle, thermal transitions and Instrumentation (Heat flux and power-compensation and designs), Modulated DSC, Hyper DSC, experimental parameters (sample preparation, experimental conditions, calibration, heating and cooling rates, resolution, source of errors) and their influence, advantage and disadvantages, pharmaceutical applications. Differential Thermal Analysis (DTA): Principle, instrumentation

and advantage and disadvantages, pharmaceutical applications, derivative differential thermal analysis (DDTA). TGA: Principle, instrumentation, factors affecting results, advantage and disadvantages, pharmaceutical applications.

#### REFERENCES

1. Spectrometric Identification of Organic compounds – Robert M Silverstein, Sixth edition, John Wiley & Sons, 2004.
2. Principles of Instrumental Analysis – Douglas A Skoog, F. James Holler, Timothy A. Nieman, 5th edition, Eastern press, Bangalore, 1998.
3. Instrumental methods of analysis – Willards, 7th edition, CBS publishers.
4. Practical Pharmaceutical Chemistry – Beckett and Stenlake, Vol II, 4th edition, CBS Publishers, New Delhi, 1997.
5. Organic Spectroscopy – William Kemp, 3rd edition, ELBS, 1991.
6. Quantitative Analysis of Drugs in Pharmaceutical formulation – P D Sethi, 3rd Edition, CBS Publishers, New Delhi, 1997.
7. Pharmaceutical Analysis– Modern methods – Part B – J W Munson, Vol 11, Marcel Dekker Series
8. Spectroscopy of Organic Compounds, 2 nd edn., P.S/Kalsi, Wiley eastern Ltd., Delhi.
9. Textbook of Pharmaceutical Analysis, KA.Connors, 3 rd Edition, John Wiley & Sons, 1982.

#### COURSE OUTCOMES

**CO1** Recognize, utilize and explain theoretical concepts, instrumentation and applications of Spectroscopic techniques like UV, IR. Fluorimetry, FES and AAS.

**CO2** Acknowledge, apply and clarify theoretical ideas, equipment, and uses of spectroscopic methods such as MR.

**CO3** Understand, apply and clarify the theoretical ideas, instrumentation and uses of spectroscopic methods such as Mass Spectroscopy (MS).

**CO4** Acknowledge, apply and clarify theoretical ideas, equipment, and uses of chromatographic methods such as gel chromatography, electrophoresis, TLC, HPTLC, Ion exchange, column GC, HPLC,affinity and X-ray crystallography.

**CO5** 5 Recognize, utilize, and explain theoretical concepts, instrumentalinn and applications of Electrophoresis and X ray Crystallngraphy.

**CO6** Explain theoretical concepts, instrumentation and applications of Potentiometry and Thermal Techniques.

**Course Outcomes and their mapping with Programme Outcomes**

CO	PO							
	PO1	PO2	PO3	PO4	PO5	PO6	PO7	PO8
CO-1								
CO-2								
CO-3								
CO-4								
CO-5								

**Weightage: 1-Sightly; 2-Moderately; 3-Strongly**

## ADVANCED PHARMACOLOGY - I (MPL 102T)

### ADVANCED PHARMACOLOGY - I (MPL 102T)

#### SCOPE

The subject is designed to strengthen the basic knowledge in the field of pharmacology and to impart recent advances in the drugs used for the treatment of various diseases. In addition, this subject helps the students to understand the concepts of drug action and mechanisms involved

#### OBJECTIVES

Upon completion of the course, student shall be able to :

- Discuss the pathophysiology and pharmacotherapy of certain diseases
- Explain the mechanism of drug actions at cellular and molecular level
- Understand the adverse effects, contraindications and clinical uses of drugs used in treatment of diseases

#### THEORY

60 Hrs

- |    |   |     |
|----|---|-----|
| 1. | General Pharmacology  | 12  |
|    | a. Pharmacokinetics: The dynamics of drug absorption, distribution, biotransformation and elimination. Concepts of linear and non-linear compartment models. Significance of Protein binding.                                 | Hrs |
|    | b. Pharmacodynamics: Mechanism of drug action and the relationship between drug concentration and effect. Receptors, structural and functional families of receptors, quantitation of drug receptors interaction and elicited |     |
| 2  | Neurotransmission   | 12  |
|    | a. General aspects and steps involved in neurotransmission.   | Hrs |
|    | b. Neurohumoral transmission in autonomic nervous system (Detailed study about neurotransmitters- Adrenaline and Acetyl choline).   |     |
|    | c. Neurohumoral transmission in central nervous system (Detailed study about neurotransmitters- histamine, serotonin, dopamine, GABA, glutamate and glycine].   |     |
|    | d. Non adrenergic non cholinergic transmission (NANC). Co-transmission  |     |

## Systemic Pharmacology

A detailed study on pathophysiology of diseases, mechanism of action, pharmacology and toxicology of existing as well as novel drugs used in the following systems

## Autonomic Pharmacology

Parasympathomimetics and lytics, sympathomimetics and lytics, agents affecting

neuromuscular junction

- |   |  |     |
|---|--|-----|
| 3 | Central nervous system Pharmacology  | 12  |
|   | General and local anesthetics  | Hrs |
|   | Sedatives and hypnotics, drugs used to treat anxiety.  |     |
|   | Depression, psychosis, mania, epilepsy, neurodegenerative diseases. Narcotic and non-narcotic analgesics.  |     |
| 4 | Cardiovascular Pharmacology  | 12  |
|   | Diuretics, antihypertensives, antiischemics, anti-arrhythmics, drugs for heart failure and hyperlipidemia. | Hrs |
|   | Hematinics, coagulants, anticoagulants, fibrinolytics and anti-platelet drugs                              |     |
| 5 | Autocoid Pharmacology  | 12  |
|   | The physiological and pathological role of Histamine, Serotonin, Kinins Prostaglandins Opioid autocoids.   |     |
|   | Pharmacology of antihistamines, 5HT antagonists.   |     |

## REFERENCES

1. The Pharmacological Basis of Therapeutics, Goodman and Gillman's
2. Principles of Pharmacology. The Pathophysiologic basis of drug Therapy by David E Golan, Armen H, Tashjian Jr, Ehrin J, Armstrong, April W, Armstrong, Wolters, Kluwer-Lippincott Williams & Wilkins Publishers.
3. Basic and Clinical Pharmacology by B.G Katzung
4. Hand book of Clinical Pharmacokinetics by Gibaldi and Prescott.
5. Applied biopharmaceutics and Pharmacokinetics by Leon Shargel and Andrew B.C.Yu.
6. Graham Smith. Oxford textbook of Clinical Pharmacology.
7. Avery Drug Treatment
8. Dipiro Pharmacology, Pathophysiological approach.
9. Green Pathophysiology for Pharmacists



10. Robbins & Cortan Pathologic Basis of Disease, 9<sup>th</sup> Ed. (Robbins Pathology)
11. A Complete Textbook of Medical Pharmacology by Dr. S.K Srivastava published by APC Avichal Publishing Company
12. KD.Tripathi. Essentials of Medical Pharmacology.
13. Modern Pharmacology with Clinical Applications, Craig Charles R. & Stitzel Robert E., Lippincott Publishers.
14. Clinical Pharmacokinetics & Pharmacodynamics: Concepts and Applications – Malcolm Rowland and Thomas N.Tozer, Wolters Kluwer, Lippincott Williams & Wilkins Publishers.
15. Applied biopharmaceutics and Pharmacokinetics, Pharmacodynamics and Drug metabolism for industrial scientists.
16. Modern Pharmacology, Craig CR. & Stitzel RE, Little Brown & Company

### **COURSE OUTCOMES**

**CO1** Discuss the General Pharmacology i.e, Pharmacokinetics and Pharmacodynamics.

**CO2** Discuss the Neurotransmission and a detailed study on Autonomic Pharmacology.

**CO3** Explain the Central nervous system Pharmacology e.g. General and local anesthetics, drugs used to treat anxiety etc.

**CO4** Explain the Cardiovascular Pharmacology e.g. Diuretics. antihypertensives, etc.

**CO5** Describe the Autocoid Pharmacology.

### **Course Outcomes and their mapping with Programme Outcomes**

<b>CO</b>	<b>PO</b>							
	<b>PO1</b>	<b>PO2</b>	<b>PO3</b>	<b>PO4</b>	<b>PO5</b>	<b>PO6</b>	<b>PO7</b>	<b>PO8</b>
CO-1								
CO-2								
CO-3								
CO-4								
CO-5								

**Weightage: 1-Sightly; 2-Moderately; 3-Strongly**

## **PHARMACOLOGICAL AND TOXICOLOGICAL SCREENING METHODS – I (MPL 103T)**

### Scope

This subject is designed to impart the knowledge on preclinical evaluation of drugs and recent experimental techniques in the drug discovery and development. The subject content helps the student to understand the maintenance of laboratory animals as per the guidelines, basic knowledge of various in-vitro and in-vivo preclinical evaluation processes

### Objectives

Upon completion of the course, student shall be able to

- Appraise the regulations and ethical requirement for the usage of experimental animals.
- Describe the various animals used in the drug discovery process and good laboratory practices in maintenance and handling of experimental animals
- Describe the various newer screening methods involved in the drug discovery process
- Appreciate and correlate the preclinical data to humans

### THEORY

60 HRS

- |    |  |           |
|----|--|-----------|
| 1. | Laboratory Animals Common laboratory animals: Description, handling and applications of different species and strains of animals.<br>Transgenic animals: Production, maintenance and applications<br>Anaesthesia and euthanasia of experimental animals.<br>Maintenance and breeding of laboratory animals.<br>CPCSEA guidelines to conduct experiments on animals<br>Good laboratory practice.<br>Bioassay–Principle, scope and limitations and Methods                                 | 12<br>Hrs |
| 2  | Preclinical screening of new substances for the pharmacological activity using in vivo, in vitro, and other possible animal alternative models.<br>General principles of preclinical screening. CNS Pharmacology: behavioral and muscle co-ordination, CNS stimulants and depressants, anxiolytics, anti-psychotics, antiepileptics and nootropics. Drugs for neurodegenerative diseases like Parkinsonism, Alzheimers and multiple sclerosis. Drugs acting on Autonomic Nervous System. | 12<br>Hrs |

- 3 Preclinical screening of new substances for the 12  
pharmacological activity using in vivo, in vitro, and other Hrs  
possible animal alternative models.

Respiratory Pharmacology: anti-asthmatics, drugs for COPD and anti allergics. Reproductive Pharmacology: Aphrodisiacs and antifertility agents Analgesics, antiinflammatory and antipyretic agents. Gastrointestinal drugs: anti ulcer, anti -emetic, anti-diarrheal and laxatives.

- 4 Preclinical screening of new substances for the 12  
pharmacological activity using in vivo, in vitro, and other Hrs  
possible animal alternative models.

Cardiovascular Pharmacology: antihypertensives, antiarrhythmics, antianginal, antiatherosclerotic agents and diuretics. Drugs for metabolic disorders like anti-diabetic, antidyslipidemic agents. Anti cancer agents. Hepatoprotective screening methods.

- 5 Preclinical screening of new substances for the 12  
pharmacological activity using in vivo, in vitro, and other Hrs  
possible animal alternative models.

Immunomodulators, Immunosuppressants and immunostimulants  
General principles of immunoassay: theoretical basis and optimization of immunoassay, heterogeneous and homogenous immunoassay systems. Immunoassay methods evaluation; protocol outline, objectives and preparation. Immunoassay for digoxin and insulin

Limitations of animal experimentation and alternate animal experiments. Extrapolation of in vitro data to preclinical and preclinical to humans

## REFERENCES

1. Biological standardization by J.H. Burn D.J. Finney and I.G. Goodwin
2. Screening methods in Pharmacology by Robert Turner. A
3. Evaluation of drugs activities by Laurence and Bachrach
4. Methods in Pharmacology by Arnold Schwartz.
5. Fundamentals of experimental Pharmacology by M.N.Ghosh
6. Pharmacological experiment on intact preparations by Churchill Livingstone

7. Drug discovery and Evaluation by Vogel H.G. 8. Experimental Pharmacology by R.K.Goyal.
8. Preclinical evaluation of new drugs by S.K. Guta
9. Handbook of Experimental Pharmacology, SK.Kulkarni
10. Practical Pharmacology and Clinical Pharmacy, SK.Kulkarni, 3<sup>rd</sup> Edition.
11. David R.Gross. Animal Models in Cardiovascular Research, 2<sup>nd</sup> Edition, Kluwer Academic Publishers, London, UK.
12. Screening Methods in Pharmacology, Robert A.Turner.
13. Rodents for Pharmacological Experiments, Dr.Tapan Kumar chatterjee.
14. Practical Manual of Experimental and Clinical Pharmacology by Bikash
15. Medhi (Author), Ajay Prakash (Author)

### **COURSE OUTCOMES**

**CO1** Describe the various Laboratory Animals i.e., Common. Transgenic. and CPCSEA guidelines, Good laboratory practice, Bioassay.

**CO2** Describe the General principles of preclinical screening.

**CO3** Preclinical screening of new substances for the pharmacological activity using in vivo, in vitro, and other possible animal alternative models particularly in Respiratory Pharmacology.

**CO4** Preclinical screening of new substances for the pharmacological activity using in vivo, in vitro, and other possible animal alternative models particularly in Cardiovascular Pharmacology.

**CO5** Describe Preclinical screening of immunomodulators and General principles of immunoassay.

### **Course Outcomes and their mapping with Programme Outcomes**

CO	PO							
	PO1	PO2	PO3	PO4	PO5	PO6	PO7	PO8
CO-1								
CO-2								
CO-3								
CO-4								
CO-5								

**Weightage: 1-Slightly; 2-Moderately; 3-Strongly**

## CELLULAR AND MOLECULAR PHARMACOLOGY (MPL 104T)

### Scope:

The subject imparts a fundamental knowledge on the structure and functions of cellular components and help to understand the interaction of these components with drugs. This information will further help the student to apply the knowledge in drug discovery process.

### Objectives:

Upon completion of the course, it is expected that the students shall be able to

- Explain the receptor signal transduction processes.
- Explain the molecular pathways affected by drugs.
- Appreciate the applicability of molecular pharmacology and biomarkers in drug discovery process.
- Demonstrate molecular biology techniques as applicable for pharmacology

### THEORY

60 Hrs

- |    |  |     |
|----|--|-----|
| 1. | Cell biology   | 12  |
|    | Structure and functions of cell and its organelles   | Hrs |
|    | Genome organization. Gene expression and its regulation, importance of siRNA and micro RNA, gene mapping and gene sequencing                                       | s   |
|    | Cell cycles and its regulation.  |     |
|    | Cell death– events, regulators, intrinsic and extrinsic pathways of apoptosis.   |     |
|    | Necrosis and autophagy.  |     |
| 2  | Cell signaling   | 12  |
|    | Intercellular and intracellular signaling pathways.  | Hrs |
|    | Classification of receptor family and molecular structure ligand gated ion channels; G–protein coupled receptors, tyrosine kinase receptors and nuclear receptors. | s   |
|    | Secondary messengers: cyclic AMP, cyclic GMP, calcium ion, inositol 1,4,5–trisphosphate, (IP3), NO, and diacylglycerol.  |     |
|    | Detailed study of following intracellular signaling pathways: cyclic AMP signaling pathway, mitogen–activated protein kinase (MAPK)                                |     |

- signaling, Janus kinase (JAK)/signal transducer and activator of transcription (STAT) signaling pathway.
- 3 Principles and applications of genomic and proteomic tools 12  
 DNA electrophoresis, PCR (reverse transcription and real time), Hr  
 Gene sequencing, micro array technique, SDS page, ELISA and s  
 western blotting,  
 Recombinant DNA technology and gene therapy  
 Basic principles of recombinant DNA technology–Restriction  
 enzymes, various types of vectors. Applications of recombinant  
 DNA technology.  
 Gene therapy– Various types of gene transfer techniques, clinical  
 applications and recent advances in gene therapy.
- 4 Pharmacogenomics  
 Gene mapping and cloning of disease gene.  
 Genetic variation and its role in health/ pharmacology  
 Polymorphisms affecting drug metabolism  
 Genetic variation in drug transporters  
 Genetic variation in G protein coupled receptors  
 Applications of proteomics science: Genomics, proteomics,  
 metabolomics, functionomics, nutrigenomics  
 Immunotherapeutics  
 Types of immunotherapeutics, humanisation antibody therapy,  
 Immunotherapeutics in clinical practice
- 5 a. Cell culture techniques  
 Basic equipments used in cell culture lab. Cell culture media,  
 various types of cell culture, general procedure for cell cultures;  
 isolation of cells, subculture, cryopreservation, characterization of  
 cells and their application.  
 Principles and applications of cell viability assays, glucose uptake  
 assay, Calcium influx assays  
 Principles and applications of flow cytometry  
 b. Biosimilars

## REFERENCES

1. The Cell, A Molecular Approach. Geoffrey M Cooper.
2. Pharmacogenomics: The Search for Individualized Therapies. Edited by J. Licinio and M –L. Wong
3. Handbook of Cell Signaling (Second Edition) Edited by Ralph A. et.al

4. Molecular Pharmacology: From DNA to Drug Discovery. John Dickenson et.al
5. Basic Cell Culture protocols by Cheril D.Helgason and Cindy L.Miller
6. Basic Cell Culture (Practical Approach ) by J. M. Davis (Editor)
7. Animal Cell Culture: A Practical Approach by John R. Masters (Editor)
8. Current porotocols in molecular biology vol I to VI edited by Frederick M.Ausuvel et la.

## **COURSE OUTCOMES**

**CO1** Explain the Cell biology.

**CO2** Explain the Cell signaling i.e., Intercellular and intracellular signaling pathways.

**CO3** Explain the Principles and applications of genomic and proteomic tools.

**CO4** Appreciate the Pharmacogenomics and Immunotherapeutics.

**CO5** Explain the Cell culture techniques and Biosimilars.

## **Course Outcomes and their mapping with Programme Outcomes**

<b>CO</b>	<b>PO</b>							
	<b>PO1</b>	<b>PO2</b>	<b>PO3</b>	<b>PO4</b>	<b>PO5</b>	<b>PO6</b>	<b>PO7</b>	<b>PO8</b>
CO-1								
CO-2								
CO-3								
CO-4								
CO-5								

**Weightage: 1-Sightly; 2-Moderately; 3-Strongly**

## **PHARMACOLOGICAL PRACTICAL - I (MPL 105P)**

1. Analysis of pharmacopoeial compounds and their formulations by UV Vis spectrophotometer
  2. Simultaneous estimation of multi component containing formulations by UV spectrophotometry
  3. Experiments based on HPLC
  4. Experiments based on Gas Chromatography
  5. Estimation of riboflavin/quinine sulphate by fluorimetry
  6. Estimation of sodium/potassium by flame photometry
- Handling of laboratory animals.
1. Various routes of drug administration.
  2. Techniques of blood sampling, anesthesia and euthanasia of experimental animals.
  3. Functional observation battery tests (modified Irwin test)
  4. Evaluation of CNS stimulant, depressant, anxiogenics and anxiolytic, anticonvulsant activity.
  5. Evaluation of analgesic, anti-inflammatory, local anesthetic, mydriatic and miotic activity.
  6. Evaluation of diuretic activity.
  7. Evaluation of antiulcer activity by pylorus ligation method.
  8. Oral glucose tolerance test.
  9. Isolation and identification of DNA from various sources (Bacteria, Cauliflower, onion, Goat liver).
  10. Isolation of RNA from yeast
  11. Estimation of proteins by Bradford/Lowry's in biological samples.
  12. Estimation of RNA/DNA by UV Spectroscopy
  13. Gene amplification by PCR.
  14. Protein quantification Western Blotting.
  15. Enzyme based in-vitro assays (MPO, AChEs,  $\alpha$  amylase,  $\alpha$  glucosidase).
  16. Cell viability assays (MTT/Trypan blue/SRB).
  17. DNA fragmentation assay by agarose gel electrophoresis.
  18. DNA damage study by Comet assay.
  19. Apoptosis determination by fluorescent imaging studies.
  20. Pharmacokinetic studies and data analysis of drugs given by different routes of administration using softwares
  21. Enzyme inhibition and induction activity



22. Extraction of drug from various biological samples and estimation of drugs in biological fluids using different analytical techniques (UV)
23. Extraction of drug from various biological samples and estimation of drugs in biological fluids using different analytical techniques (HPLC)

## REFERENCES

1. CPCSEA, OECD, ICH, USFDA, Schedule Y, EPA guidelines,
2. Fundamentals of experimental Pharmacology by M.N.Ghosh
3. Handbook of Experimental Pharmacology by S.K. Kulkarni.
4. Drug discovery and Evaluation by Vogel H.G.
5. Spectrometric Identification of Organic compounds – Robert M Silverstein,
6. Principles of Instrumental Analysis – Douglas A Skoog, F. James Holler, Timothy A. Nieman,
7. Vogel's Text book of quantitative chemical analysis – Jeffery, Basset, Mendham, Denney,
8. Basic Cell Culture protocols by Cheril D. Helgason and Cindy L.Mille
9. Basic Cell Culture (Practical Approach ) by J. M. Davis (Editor)
10. Animal Cell Culture: A Practical Approach by John R. Masters (Editor)
11. Practical Manual of Experimental and Clinical Pharmacology by Bikash Medhi(Author), Ajay Prakash (Author) Jaypee brothers' medical publishers Pvt. Ltd

## COURSE OUTCOMES

- CO1** Discuss the General Pharmacology i.e, Pharmacokinetics and Pharmacodynamics.
- CO2** Discuss the Neurotransmission and a detailed study on Autonomic Pharmacology.
- CO3** Explain the Central nervous system Pharmacology e.g. General and local anesthetics, drugs used to treat anxiety etc.
- CO4** Explain the Cardiovascular Pharmacology e.g. Diuretics. antihypertensives, etc.
- CO5** Describe the Autocoid Pharmacology.

**Course Outcomes and their mapping with Programme Outcomes**

CO	PO							
	PO1	PO2	PO3	PO4	PO5	PO6	PO7	PO8
CO-1								
CO-2								
CO-3								
CO-4								
CO-5								

**Weightage: 1-Sightly; 2-Moderately; 3-Strongly**

## **SEMESTER II**

## ADVANCED PHARMACOLOGY - II (MPL 201T)

### Scope

The subject is designed to strengthen the basic knowledge in the field of pharmacology and to impart recent advances in the drugs used for the treatment of various diseases. In addition, the subject helps the student to understand the concepts of drug action and mechanism involved

### Objectives

Upon completion of the course the student shall be able to:

- Explain the mechanism of drug actions at cellular and molecular level
- Discuss the Pathophysiology and pharmacotherapy of certain diseases
- Understand the adverse effects, contraindications and clinical uses of drugs used in treatment of diseases

### THEORY

60 Hrs

- |    |   |     |
|----|---|-----|
| 1. | Endocrine Pharmacology  | 12  |
|    | Molecular and cellular mechanism of action of hormones such as growth hormone, prolactin, thyroid, insulin and sex hormones                         | Hrs |
|    | Anti-thyroid drugs, Oral hypoglycemic agents, Oral contraceptives, Corticosteroids.   |     |
|    | Drugs affecting calcium regulation  |     |
| 2  | Chemotherapy  | 12  |
|    | Cellular and molecular mechanism of actions and resistance of antimicrobial agents  | Hrs |
|    | such as $\beta$ -lactams, aminoglycosides, quinolones, Macrolide antibiotics. Antifungal, antiviral, and anti-TB drugs.                             |     |
| 3  | Chemotherapy  | 12  |
|    | Drugs used in Protozoal Infections  | Hrs |
|    | Drugs used in the treatment of Helminthiasis  |     |
|    | Chemotherapy of cancer  |     |
|    | Immunopharmacology  |     |
|    | Cellular and biochemical mediators of inflammation and immune response. Allergic or hypersensitivity reactions. Pharmacotherapy of asthma and COPD. |     |
|    | Immunosuppressants and Immunostimulants   |     |

4	GIT Pharmacology	12
	Antiulcer drugs, Prokinetics, antiemetics, anti-diarrheals and drugs for constipation and irritable bowel syndrome.	Hrs
	Chronopharmacology	
	Biological and circadian rhythms, applications of chronotherapy in various diseases like cardiovascular disease, diabetes, asthma and peptic ulcer	
5	Free radicals Pharmacology	12
	Generation of free radicals, role of free radicals in etiopathology of various diseases such as diabetes, neurodegenerative diseases and cancer.	Hrs
	Protective activity of certain important antioxidant	
	Recent Advances in Treatment:	
	Alzheimer's disease, Parkinson's disease, Cancer, Diabetes mellitus	

## REFERENCES

1. The Pharmacological basis of therapeutics– Goodman and Gill man's
2. Principles of Pharmacology. The Pathophysiologic basis of drug therapy by David E Golan et al.
3. Basic and Clinical Pharmacology by B.G –Katzung
4. Pharmacology by H.P. Rang and M.M. Dale.
5. Hand book of Clinical Pharmacokinetics by Gibaldi and Prescott.
6. Text book of Therapeutics, drug and disease management by E T. Herfindal and Gourley.
7. Applied biopharmaceutics and Pharmacokinetics by Leon Shargel and Andrew B.C.Yu.
8. Handbook of Essential Pharmacokinetics, Pharmacodynamics and Drug Metabolism for Industrial Scientists
9. Robbins & Cortan Pathologic Basis of Disease, 9 th Ed. (Robbins Pathology)
10. A Complete Textbook of Medical Pharmacology by Dr. S.K Srivastava published by APC Avichal Publishing Company.
11. KD.Tripathi. Essentials of Medical Pharmacology
12. Principles of Pharmacology. The Pathophysiologic basis of drug Therapy by David E Golan, Armen H, Tashjian Jr, Ehrin J,Armstrong, April W. Armstrong , Wolter, Kluwer–Lippincott Williams & Publishers

## **COURSE OUTCOMES**

**CO1** Describe the Endocrine Pharmacology.

**CO2** Explain Chemotherapy particularly Cellular and molecular mechanism of actions and resistance of antimicrobial agents such as B-lactams, aminoglycosides, quinolones, etc.

**CO3** To know about the Chemotherapy i., Drugs used in Protozoal Infections, cancer, immune disorders, inflammation, asthma etc.

**CO4** Describe the GIT Pharmacology.

**CO5** Explain Free radicals Pharmacology

### **Course Outcomes and their mapping with Programme Outcomes**

<b>CO</b>	<b>PO</b>							
	<b>PO1</b>	<b>PO2</b>	<b>PO3</b>	<b>PO4</b>	<b>PO5</b>	<b>PO6</b>	<b>PO7</b>	<b>PO8</b>
CO-1								
CO-2								
CO-3								
CO-4								
CO-5								

**Weightage: 1-Sightly; 2-Moderately; 3-Strongly**

## PHARMACOLOGICAL AND TOXICOLOGICAL SCREENING METHODS-II (MPL 202T)

### Scope

This subject imparts knowledge on the preclinical safety and toxicological evaluation of drug & new chemical entity. This knowledge will make the student competent in regulatory toxicological evaluation.

### Objectives

Upon completion of the course, the student shall be able to,

- Explain the various types of toxicity studies.
- Appreciate the importance of ethical and regulatory requirements for toxicity studies.
- Demonstrate the practical skills required to conduct the preclinical toxicity studies.

### THEORY

60 Hrs

1. Basic definition and types of toxicology (general, mechanistic, regulatory and descriptive) 12 Hrs  
Regulatory guidelines for conducting toxicity studies OECD, ICH, EPA and Schedule Y  
OECD principles of Good laboratory practice (GLP)  
History, concept and its importance in drug development
2. Acute, sub-acute and chronic- oral, dermal and inhalational studies as per OECD guidelines. 12 Hrs  
Acute eye irritation, skin sensitization, dermal irritation & dermal toxicity studies.  
Test item characterization- importance and methods in regulatory toxicology
3. Reproductive toxicology studies, Male reproductive toxicity studies, female reproductive studies (segment I and segment III), teratogenicity studies (segment II) 12 Hrs  
Genotoxicity studies (Ames Test, in vitro and in vivo Micronucleus and Chromosomal aberrations studies)  
In vivo carcinogenicity studies
4. IND enabling studies (IND studies)- Definition of IND, importance of IND, industry perspective, list of studies needed for IND submission. 12 Hrs

Safety pharmacology studies– origin, concepts and importance of safety pharmacology.

Tier1– CVS, CNS and respiratory safety pharmacology, HERG assay. Tier2– GI, renal and other studies

- 5 Toxicokinetics– Toxicokinetic evaluation in preclinical studies, 12 saturation kinetics Importance and applications of toxicokinetic Hrs studies. Alternative methods to animal toxicity testing.

## REFERENCES

1. Hand book on GLP, Quality practices for regulated non-clinical research and development (<http://www.who.int/tdr/publications/documents/glp-handbook.pdf>).
2. Schedule Y Guideline: drugs and cosmetics (second amendment) rules, 2005, ministry of health and family welfare (department of health) New Delhi
3. Drugs from discovery to approval by Rick NG.
4. Animal Models in Toxicology, 3rd Edition, Lower and Bryan
5. OECD test guidelines.
6. Principles of toxicology by Karen E. Stine, Thomas M. Brown.
7. Guidance for Industry M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals (<http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm073246.pdf>)

## COURSE OUTCOMES

**CO1** To know about the Basic definition and types of toxicology, Regulatory guidelines for conducting toxicity studies OECD, ICH etc.

**CO2** Describe the Acute, subacute and chronic- oral, dermal and inhalational studies as per OECD.

**CO3** guidelines Explain Reproductive toxicology studies.

**CO4** To know about the IND enabling studies (IND studies).

**CO5** Describe the Toxicokinetics.



### Course Outcomes and their mapping with Programme Outcomes

CO	PO							
	PO1	PO2	PO3	PO4	PO5	PO6	PO7	PO8
CO-1								
CO-2								
CO-3								
CO-4								
CO-5								

**Weightage: 1-Sightly; 2-Moderately; 3-Strongly**

## **PRINCIPLES OF DRUG DISCOVERY (MPL 203T)**

### Scope

The subject imparts basic knowledge of drug discovery process. This information will make the student competent in drug discovery process

### Objectives

Upon completion of this course it is expected that students will be able to

- Explain the various stages of drug discovery.
- Appreciate the importance of the role of genomics, proteomics and bioinformatics in drug discovery
- Explain various targets for drug discovery.
- Explain various lead seeking method and lead optimization
- Appreciate the importance of the role of computer aided drug design in drug discovery

### THEORY

60 Hrs

1. An overview of modern drug discovery process: Target identification, target validation, lead identification and lead Optimization. Economics of drug discovery. 12 Hrs

Target Discovery and validation–Role of Genomics, Proteomics and Bioinformatics. Role of Nucleic acid microarrays, Protein microarrays, Antisense technologies, siRNAs, antisense oligonucleotides, Zinc finger proteins. Role of transgenic animals in target validation.

- 2 Lead Identification– combinatorial chemistry & high throughput screening, in silico lead discovery techniques, Assay development for hit identification. 12 Hrs

#### Protein structure

Levels of protein structure, Domains, motifs, and folds in protein structure. Computational prediction of protein structure: Threading and homology modeling methods. Application of NMR and X-ray crystallography in protein structure prediction

3	Rational Drug Design	12
	Traditional vs rational drug design, Methods followed in traditional drug design, High throughput screening, Concepts of Rational Drug Design, Rational Drug Design Methods: Structure and Pharmacophore based approaches	Hrs
	Virtual Screening techniques: Drug likeness screening, Concept of pharmacophore mapping and pharmacophore based Screening,	
4	Molecular docking: Rigid docking, flexible docking, manual docking; Docking based screening. De novo drug design.	12
	Quantitative analysis of Structure Activity Relationship	Hrs
	History and development of QSAR, SAR versus QSAR, Physicochemical parameters, Hansch analysis, Fee Wilson analysis and relationship between them.	
5	QSAR Statistical methods – regression analysis, partial least square analysis (PLS) and other multivariate statistical methods.	12
	3D-QSAR approaches like COMFA and COMSIA	Hrs
	Prodrug design–Basic concept, Prodrugs to improve patient acceptability, Drug solubility, Drug absorption and distribution, site specific drug delivery and sustained drug action. Rationale of prodrug design and practical consideration of prodrug	

## REFERENCES

1. MouldySioud. Target Discovery and Validation Reviews and Protocols: Volume 2 Emerging Molecular Targetsand Treatment Options. 2007 Humana Press Inc.
2. Darryl León. Scott MarkellIn. Silico Technologies in Drug Target Identification and Validation. 2006 by Taylor and Francis Group, LLC.
3. Johanna K. DiStefano. Disease Gene Identification. Methods and Protocols. Springer New York Dordrecht Heidelberg London.
4. Hugo Kubiny. QSAR: Hansch Analysis and Related Approaches. Methods and Principles in Medicinal Chemistry. Publisher Wiley–VCH
5. Klaus Gubernator, Hans-Joachim Böhm. Structure-Based Ligand Design. Methods and Principles in Medicinal Chemistry. Publisher Wiley–VCH
6. Abby L . Parrill. M . Rami Reddy. Rational Drug Design. Novel Methodology and Practical Applications. ACS Symposium Series; American Chemical Society: Washington, DC, 1999.

7. J. Rick Turner. New drug development design, methodology and, analysis.  
John Wiley & Sons, Inc., New Jersey

### **COURSE OUTCOMES**

**CO1** To know about the modern drug discovery process.

**CO2** Describe the Lead Identification i.e., combinatorial chemistry & high throughput screening, in silico lead discovery techniques, Assay development for hit identification

**CO3** To know about the Rational Drug Design.

**CO4** Explain Molecular docking and OSAR.

**CO5** Describe the QSAR Statistical methods and prodrug design.

### **Course Outcomes and their mapping with Programme Outcomes**

<b>CO</b>	<b>PO</b>							
	<b>PO1</b>	<b>PO2</b>	<b>PO3</b>	<b>PO4</b>	<b>PO5</b>	<b>PO6</b>	<b>PO7</b>	<b>PO8</b>
CO-1								
CO-2								
CO-3								
CO-4								
CO-5								

**Weightage: 1-Sightly; 2-Moderately; 3-Strongly**

## CLINICAL RESEARCH AND PHARMACOVIGILANCE (MPL 204T)

### Scope

This subject will provide a value addition and current requirement for the students in clinical research and pharmacovigilance. It will teach the students on conceptualizing, designing, conducting, managing and reporting of clinical trials.

This subject also focuses on global scenario of Pharmacovigilance in different methods that can be used to generate safety data. It will teach the students in developing drug safety data in Pre-clinical, Clinical phases of Drug development and post market surveillance.

### Objectives

Upon completion of the course, the students shall be able to,

- Explain the regulatory requirements for conducting clinical trial
- Demonstrate the types of clinical trial designs
- Explain the responsibilities of key players involved in clinical trials
- Execute safety monitoring, reporting and close-out activities
- Explain the principles of Pharmacovigilance
- Detect new adverse drug reactions and their assessment
- Perform the adverse drug reaction reporting systems and communication in Pharmacovigilance

### THEORY

60 Hrs

- |  |     |
|--|-----|
| 1. Regulatory Perspectives of Clinical Trials:   | 12  |
| Origin and Principles of International Conference on Harmonization – Good Clinical Practice (ICH–GCP) guidelines                     | Hrs |
| Ethical Committee: Institutional Review Board, Ethical Guidelines for Biomedical Research and Human Participant– Schedule Y, ICMR    |     |
| Informed Consent Process: Structure and content of an Informed Consent Process Ethical principles governing informed consent process |     |
| 2 Clinical Trials: Types and Design  | 12  |
| Experimental Study– RCT and Non RCT,   | Hrs |
| Observation Study: Cohort, Case Control, Cross sectional   |     |

## Clinical Trial Study Team

Roles and responsibilities of Clinical Trial Personnel: Investigator, Study Coordinator, Sponsor, Contract Research Organization and its management

- |   |   |           |
|---|---|-----------|
| 3 | Clinical Trial Documentation– Guidelines to the preparation of documents, Preparation of protocol, Investigator Brochure, Case Report Forms, Clinical Study Report Clinical Trial Monitoring Safety Monitoring in CT<br>Adverse Drug Reactions: Definition and types. Detection and reporting methods. Severity and seriousness assessment. Predictability and preventability assessment, Management of adverse drug reactions; Terminologies of ADR.   | 12<br>Hrs |
| 4 | Basic aspects, terminologies and establishment of pharmacovigilance<br>History and progress of pharmacovigilance, Significance of safety monitoring, Pharmacovigilance in India and international aspects, WHO international drug monitoring programme, WHO and Regulatory terminologies of ADR, evaluation of medication safety, Establishing pharmacovigilance centres in Hospitals, Industry and National programmes related to pharmacovigilance. Roles and responsibilities in Pharmacovigilance   | 12<br>Hrs |
| 5 | Methods, ADR reporting and tools used in Pharmacovigilance<br>International classification of diseases, International Non-proprietary names for drugs, Passive and Active surveillance, Comparative observational studies, Targeted clinical investigations and Vaccine safety surveillance. Spontaneous reporting system and Reporting to regulatory authorities, Guidelines for ADRs reporting. Argus, Aris G Pharmacovigilance, VigiFlow, Statistical methods for evaluating medication safety data. | 12<br>Hrs |
| 6 | Pharmacoepidemiology, pharmacoconomics, safety pharmacology   | 12<br>Hrs |

## REFERENCES

1. Central Drugs Standard Control Organization– Good Clinical Practices, Guidelines for Clinical Trials on Pharmaceutical Products in India. New Delhi: Ministry of Health;2001.

2. International Conference on Harmonization of Technical requirements for registration of Pharmaceuticals for human use. ICH Harmonized Tripartite Guideline. Guideline for Good Clinical Practice.E6; May 1996. 229
3. Ethical Guidelines for Biomedical Research on Human Subjects 2000. Indian Council of Medical Research, New Delhi.
4. Textbook of Clinical Trials edited by David Machin, Simon Day and Sylvan Green, March 2005, John Wiley and Sons.
5. Clinical Data Management edited by R K Rondels, S A Varley, C F Webbs. Second Edition, Jan 2000, Wiley Publications.
6. Handbook of clinical Research. Julia Lloyd and Ann Raven Ed. Churchill Livingstone.
7. Principles of Clinical Research edited by Giovanna di Ignazio, Di Giovanna and Haynes.

## **COURSE OUTCOMES**

**CO1** Explain the Regulatory Perspectives of Clinical.

**CO2** Trials. Describe the Clinical Trials.

**CO3** To know about the Clinical Trial Documentation and Adverse Drug Reactions.

**CO4** Explain the Basic aspects, terminologies and establishment of pharmacovigilance.

**CO5** Explain the Methods, ADR reporting and tools used in Pharmacovigilance.

**CO6** Describe the Pharmacoepidemiology, pharmacoeconomics, safety pharmacology

## **Course Outcomes and their mapping with Programme Outcomes**

<b>CO</b>	<b>PO</b>							
	<b>PO1</b>	<b>PO2</b>	<b>PO3</b>	<b>PO4</b>	<b>PO5</b>	<b>PO6</b>	<b>PO7</b>	<b>PO8</b>
CO-1								
CO-2								
CO-3								
CO-4								
CO-5								

**Weightage: 1-Sightly; 2-Moderately; 3-Strongly**

## PHARMACOLOGICAL PRACTICAL – II (MPL 205P)

1. To record the DRC of agonist using suitable isolated tissues preparation.
2. To study the effects of antagonist/potentiating agents on DRC of agonist using suitable isolated tissue preparation.
3. To determine to the strength of unknown sample by matching bioassay by using suitable tissue preparation.
4. To determine to the strength of unknown sample by interpolation bioassay by using suitable tissue preparation
5. To determine to the strength of unknown sample by bracketing bioassay by using suitable tissue preparation
6. To determine to the strength of unknown sample by multiple point bioassay by using suitable tissue preparation.
7. Estimation of PA<sub>2</sub> values of various antagonists using suitable isolated tissue preparations.
8. To study the effects of various drugs on isolated heart preparations
9. Recording of rat BP, heart rate and ECG.
10. Recording of rat ECG
11. Drug absorption studies by averted rat ileum preparation.
12. Acute oral toxicity studies as per OECD guidelines.
13. Acute dermal toxicity studies as per OECD guidelines.
14. Repeated dose toxicity studies– Serum biochemical, haematological, urine analysis, functional observation tests and histological studies.
15. Drug mutagenicity study using mice bone–marrow chromosomal aberration test.
16. Protocol design for clinical trial.(3 Nos.).
17. Design of ADR monitoring protocol.
18. In–silico docking studies. (2 Nos.)
19. In–silico pharmacophore based screening.
20. In–silico QSAR studies.
21. ADR reporting

## REFERENCES

1. Fundamentals of experimental Pharmacology–by M.N.Ghosh
2. Hand book of Experimental Pharmacology–S.K.Kulakarni
3. Text book of in–vitro practical Pharmacology by Ian Kitchen



4. Bioassay Techniques for Drug Development by Atta-ur-Rahman, Iqbal choudhary and William Thomsen
5. Applied biopharmaceutics and Pharmacokinetics by Leon Shargel and Andrew B.C.Yu.
6. Handbook of Essential Pharmacokinetics, Pharmacodynamics and Drug Metabolism for Industrial Scientists.

## **COURSE OUTCOMES**

**CO1** Describe the Endocrine Pharmacology.

**CO2** Explain Chemotherapy particularly Cellular and molecular mechanism of actions and resistance of antimicrobial agents such as B-lactams, aminoglycosides, quinolones, etc.

**CO3** To know about the Chemotherapy i., Drugs used in Protozoal Infections, cancer, immune disorders, inflammation, asthma etc.

**CO4** Describe the GIT Pharmacology.

**CO5** Explain Free radicals Pharmacology

## **Course Outcomes and their mapping with Programme Outcomes**

<b>CO</b>	<b>PO</b>							
	<b>PO1</b>	<b>PO2</b>	<b>PO3</b>	<b>PO4</b>	<b>PO5</b>	<b>PO6</b>	<b>PO7</b>	<b>PO8</b>
CO-1								
CO-2								
CO-3								
CO-4								
CO-5								

**Weightage: 1-Slightly; 2-Moderately; 3-Strongly**

## **SEMESTER III**

## **RESEARCH METHODOLOGY & BIOSTATISTICS (MRM 301T)**

### **UNIT – I**

General Research Methodology: Research, objective, requirements, practical difficulties, review of literature, study design, types of studies, strategies to eliminate errors/bias, controls, randomization, crossover design, placebo, blinding techniques.

### **UNIT – II**

Biostatistics: Definition, application, sample size, importance of sample size, factors influencing sample size, dropouts, statistical tests of significance, type of significance tests, parametric tests (students “t” test, ANOVA, Correlation coefficient, regression), non-parametric tests (wilcoxon rank tests, analysis of variance, correlation, chi square test), null hypothesis, P values, degree of freedom, interpretation of P values.

### **UNIT – III**

Medical Research: History, values in medical ethics, autonomy, beneficence, non-maleficence, double effect, conflicts between autonomy and beneficence/non-maleficence, euthanasia, informed consent, confidentiality, criticisms of orthodox medical ethics, importance of communication, control resolution, guidelines, ethics committees, cultural concerns, truth telling, online business practices, conflicts of interest, referral, vendor relationships, treatment of family members, sexual relationships, fatality.

### **UNIT – IV**

CPCSEA guidelines for laboratory animal facility: Goals, veterinary care, quarantine, surveillance, diagnosis, treatment and control of disease, personal hygiene, location of animal facilities to laboratories, anesthesia, euthanasia, physical facilities, environment, animal husbandry, record keeping, SOPs, personnel and training, transport of lab animals.

### **UNIT – V**

Declaration of Helsinki: History, introduction, basic principles for all medical research, and additional principles for medical research combined with medical care.

## **COURSE OUTCOMES**

**CO1** Describe the General Research Methodology.

**CO2** Explain Biostatistics i.e., sample size, statistical tests of significance, Biostatistics\* parametric tests, non-parametric tests, analysis of variance etc.

**CO3** To know about the Medical Research i.e., History, values in medical ethics, autonomy, beneficence, non- maleficence etc.

**CO4** Describe the CPCSEA guidelines for laboratory animal facility.

**CO5** Explain Declaration of Helsinki

**Course Outcomes and their mapping with Programme Outcomes**

<b>CO</b>	<b>PO</b>							
	<b>PO1</b>	<b>PO2</b>	<b>PO3</b>	<b>PO4</b>	<b>PO5</b>	<b>PO6</b>	<b>PO7</b>	<b>PO8</b>
CO-1								
CO-2								
CO-3								
CO-4								
CO-5								

**Weightage: 1-Sightly; 2-Moderately; 3-Strongly**